Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Hypoparathyroidism: is it that easy to treat?

Hypoparathyroidism: is it that easy to treat? Hypoparathyroidism is a relatively rare endocrine disease characterised by either null or inappropriately low secretion of parathyroid hormone (PTH) for serum calcium levels. The other main laboratory findings include hypocalcaemia, inappropriately normal or high urine calcium excretion and hyperphosphataemia with low urine phosphate excretion. The management of hypoparathyroidism should be tailored to each individual case, which makes it a demanding undertaking in everyday clinical practice. In this review, we sought to focus on the diagnostic approach of hypoparathyroidism and the therapeutic challenges of the disease from a clinical perspective. Conventional treatment with vitamin D analogues and calcium salts is no longer the only available treatment, since replacement treatment with PTH(1-84) has recently been approved for the disease. However, the optimal treatment schedule is yet to be defined. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hormones Springer Journals

Hypoparathyroidism: is it that easy to treat?

Download PDF
9 pages
Read Article

Loading next page...
 
/lp/springer_journal/hypoparathyroidism-is-it-that-easy-to-treat-BAA2IA6MID
Publisher
Springer Journals
Copyright
Copyright © 2018 by Hellenic Endocrine Society
Subject
Medicine & Public Health; Medicine/Public Health, general; Endocrinology; Metabolic Diseases
ISSN
1109-3099
eISSN
2520-8721
DOI
10.1007/s42000-018-0032-6
Publisher site
See Article on Publisher Site

Abstract

Hypoparathyroidism is a relatively rare endocrine disease characterised by either null or inappropriately low secretion of parathyroid hormone (PTH) for serum calcium levels. The other main laboratory findings include hypocalcaemia, inappropriately normal or high urine calcium excretion and hyperphosphataemia with low urine phosphate excretion. The management of hypoparathyroidism should be tailored to each individual case, which makes it a demanding undertaking in everyday clinical practice. In this review, we sought to focus on the diagnostic approach of hypoparathyroidism and the therapeutic challenges of the disease from a clinical perspective. Conventional treatment with vitamin D analogues and calcium salts is no longer the only available treatment, since replacement treatment with PTH(1-84) has recently been approved for the disease. However, the optimal treatment schedule is yet to be defined.

Journal

Hormones – Springer Journals

Published: Jun 6, 2018

References

  • Diagnosis and management of hypocalcaemia
    Cooper, MS; Gittoes, NJ
  • Review of hypoparathyroidism
    Abate, EG; Clarke, BL
  • Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research
    Bilezikian, JP; Khan, A; Potts, JT; Brandi, ML; Clarke, BL; Shoback, D
  • Prevalence and incidence of hypoparathyroidism in the United States using a large claims database
    Powers, J; Joy, K; Ruscio, A; Lagast, H
  • Long-term follow-up of patients with hypoparathyroidism
    Mitchell, DM; Regan, S; Cooley, MR; Lauter, KB; Vrla, MC; Becker, CB
  • Impact of postoperative magnesium levels on early hypocalcemia and permanent hypoparathyroidism after thyroidectomy
    Garrahy, A; Murphy, MS; Sheahan, P
  • Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation
    Nakamoto, JM; Sandstrom, AT; Brickman, AS; Christenson, RA; Dop, C
  • Albright hereditary osteodystrophy
    Stieler, K; Schnabel, D; Atugoda, S; Sterry, W; Blume-Peytavi, U
  • Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations
    Elli, FM; deSanctis, L; Ceoloni, B; Barbieri, AM; Bordogna, P; Beck-Peccoz, P; Spada, A; Mantovani, G
  • Clinical practice: hypoparathyroidism
    Shoback, D
  • Presentation of hypoparathyroidism: etiologies and clinical features
    Shoback, DM; Bilezikian, JP; Costa, AG; Dempster, D; Dralle, H; Khan, AA
  • Calcification of the basal ganglia in chronic hypoparathyroidism
    Rastogi, R; Beauchamp, NJ; Ladenson, PW
  • Bilateral striopallidodentate calcification (Fahr's syndrome) and multiple system atrophy in a patient with longstanding hypoparathyroidism
    Preusser, M; Kitzwoegerer, M; Budka, H; Brugger, S
  • Three dimensional cancellous bone structure in hypoparathyroidism
    Rubin, MR; Dempster, DW; Kohler, T; Stauber, M; Zhou, H; Shane, E
  • Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement
    Rubin, MR; Bilezikian, JP
  • Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism
    Cusano, NE; Nishiyama, KK; Zhang, C; Rubin, MR; Boutroy, S; McMahon, DJ
  • Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies
    Christen, P; Ito, K; Muller, R; Rubin, MR; Dempster, DW; Bilezikian, JP
  • The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study
    Underbjerg, L; Sikjaer, T; Mosekilde, L; Rejnmark, L
  • Postsurgical hypoparathyroidism—risk of fractures, psychiatric diseases, cancer, cataract, and infections
    Underbjerg, L; Sikjaer, T; Mosekilde, L; Rejnmark, L
  • Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density
    Mendonca, ML; Pereira, FA; Nogueira-Barbosa, MH; Monsignore, LM; Teixeira, SR; Watanabe, PC
  • Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review
    Buttner, M; Musholt, TJ; Singer, S
  • Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism
    Sikjaer, T; Moser, E; Rolighed, L; Underbjerg, L; Bislev, LS; Mosekilde, L; Rejnmark, L
  • Quality of life in hypoparathyroidism
    Rejnmark, L
  • Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism
    Winer, KK; Zhang, B; Shrader, JA; Peterson, D; Smith, M; Albert, PS
  • Regulation of calcium homeostasis and genetic disorders that affect calcium metabolism
    Thakker, RVBF; Jόppner, H
  • Investigating hypocalcaemia
    Hannan, FM; Thakker, RV
  • Vitamin D deficiency rickets mimicking pseudohypoparathyroidism
    Akin, L; Kurtoglu, S; Yildiz, A; Akin, MA; Kendirici, M
  • Management of hypoparathyroidism: summary statement and guidelines
    Brandi, ML; Bilezikian, JP; Shoback, D; Bouillon, R; Clarke, BL; Thakker, RV
  • Management of hypoparathyroidism: present and future
    Bilezikian, JP; Brandi, ML; Cusano, NE; Mannstadt, M; Rejnmark, L; Rizzoli, R; Rubin, MR; Winer, KK; Liberman, UA; Potts, JT
  • Treatment of chronic hypoparathyroidism in adults
    Bollerslev, J; Rejnmark, L; Marcocci, C; Shoback, DM; Sitges-Serra, A; Biesen, W
  • American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: postoperative hypoparathyroidism—definitions and management
    Stack, BC; Bimston, DN; Bodenner, DL; Brett, EM; Dralle, H; Orloff, LA
  • Hypoparathyroidism: less severe hypocalcemia with treatment with vitamin D2 compared with calcitriol
    Streeten, EA; Mohtasebi, Y; Konig, M; Davidoff, L; Ryan, K
  • Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure
    Spaia, S
  • Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism
    Winer, KK; Yanovski, JA; Cutler, GB
  • Teriparatide therapy and reduced postoperative hospitalization for postsurgical hypoparathyroidism
    Shah, M; Bancos, I; Thompson, GB; Richards, ML; Kasperbauer, JL; Clarke, BL
  • PTH(1-34) for surgical hypoparathyroidism: a 2 year prospective, open-label investigation of efficacy and quality of life
    Palermo, A; Santonati, A; Tabacco, G; Bosco, D; Spada, A; Pedone, C
  • Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism
    Winer, KK; Sinaii, N; Peterson, D; Sainz, B; Cutler, GB
  • Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium
    Winer, KK; Sinaii, N; Reynolds, J; Peterson, D; Dowdy, K; Cutler, GB
  • Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism
    Winer, KK; Fulton, KA; Albert, PS; Cutler, GB
  • Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study
    Clarke, BL; Kay Berg, J; Fox, J; Cyran, JA; Lagast, H
  • Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety
    Rubin, MR; Cusano, NE; Fan, WW; Delgado, Y; Zhang, C; Costa, AG
  • Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study
    Mannstadt, M; Clarke, BL; Vokes, T; Brandi, ML; Ranganath, L; Fraser, WD
  • Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
    Clarke, BL; Vokes, TJ; Bilezikian, JP; Shoback, DM; Lagast, H; Mannstadt, M
  • PTH(1-84) administration in hypoparathyroidism transiently reduces bone matrix mineralization
    Misof, BM; Roschger, P; Dempster, DW; Zhou, H; Bilezikian, JP; Klaushofer, K
  • An open-label extension study of parathyroid hormone Rhpth(1-84) in adults with hypoparathyroidism
    Lakatos, P; Bajnok, L; Lagast, H; Valkusz, Z
  • Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25-mug or 50-mug daily doses
    Bilezikian, JP; Clarke, BL; Mannstadt, M; Rothman, J; Vokes, T; Lee, HM
  • PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy
    Cusano, NE; Rubin, MR; McMahon, DJ; Irani, D; Anderson, L; Levy, E
  • Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial
    Sikjaer, T; Rolighed, L; Hess, A; Fuglsang-Frederiksen, A; Mosekilde, L; Rejnmark, L
  • PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life
    Santonati, A; Palermo, A; Maddaloni, E; Bosco, D; Spada, A; Grimaldi, F
  • PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation
    Theman, TA; Collins, MT; Dempster, DW; Zhou, H; Reynolds, JC; Brahim, JS
  • Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety
    Cusano, NE; Rubin, MR; McMahon, DJ; Zhang, C; Ives, R; Tulley, A
  • Recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study
    Clarke, BV; Vokes, TJ; Bilezikian, JP
  • Safety of osteoanabolic therapy: a decade of experience
    Cipriani, C; Irani, D; Bilezikian, JP
  • The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years
    Andrews, EB; Gilsenan, AW; Midkiff, K; Sherrill, B; Wu, Y; Mann, BH
  • Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program
    Mirabello, L; Troisi, RJ; Savage, SA
  • Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
    Vahle, JL; Sato, M; Long, GG; Young, JK; Francis, PC; Engelhardt, JA
  • Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats
    Jolette, J; Wilker, CE; Smith, SY; Doyle, N; Hardisty, JF; Metcalfe, AJ
  • Lawrence G. Raisz November 13, 1925-August 25, 2010
    Bilezikian, JP; Drezner, M; Kream, B; Stern, P; Clemens, T; Elderkin, A

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

Sign up
for free
Start 14 day
Free Trial